Successful treatment of advanced Birt-Hogg-Dubé syndrome-associated renal cell carcinoma with sarcomatoid dedifferentiation using anlotinib combined with PD-1 inhibitor after first-line therapy failure: a case report
Yi L, Li C, Xu D, Xu L. Successful treatment of advanced Birt-Hogg-Dubé syndrome-associated renal cell carcinoma with sarcomatoid dedifferentiation using anlotinib combined with PD-1 inhibitor after first-line therapy failure: a case report. World Journal Of Surgical Oncology 2025, 23: 299. PMID: 40707936, PMCID: PMC12291473, DOI: 10.1186/s12957-025-03941-9.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaSarcomatoid dedifferentiationCell carcinomaBRCA2 mutationsRoutine monitoring of blood countsTreatment challengesEfficacy of targeted immunotherapyDiagnosis of renal cell carcinomaMonitoring of blood countsSarcomatoid renal cell carcinomaDevelopment of individualized treatment strategiesFirst-line therapy failureRadical left nephrectomyPD-1 inhibitorsLeft renal massLymph node dissectionSecond-line therapySecond-line treatmentIndividualized treatment strategiesMonths post-operationPotential therapeutic optionRECIST1.1 criteriaPD-1Node dissectionPartial response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply